1. Home
  2. TECX vs CEPV Comparison

TECX vs CEPV Comparison

Compare TECX & CEPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$29.47

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

CEPV

Cantor Equity Partners V Inc. Class A Ordinary Shares

N/A

Current Price

$10.13

Market Cap

322.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TECX
CEPV
Founded
2019
2021
Country
United States
United States
Employees
51
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
393.0M
322.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TECX
CEPV
Price
$29.47
$10.13
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$80.40
N/A
AVG Volume (30 Days)
323.2K
48.4K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$10.10
52 Week High
$35.99
$10.35

Technical Indicators

Market Signals
Indicator
TECX
CEPV
Relative Strength Index (RSI) 54.30 44.16
Support Level $16.83 $10.10
Resistance Level $35.99 $10.18
Average True Range (ATR) 2.85 0.02
MACD -0.27 0.00
Stochastic Oscillator 55.28 33.33

Price Performance

Historical Comparison
TECX
CEPV

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About CEPV Cantor Equity Partners V Inc. Class A Ordinary Shares

Cantor Equity Partners V Inc is a blank check company.

Share on Social Networks: